PCA Investment Advisory Services’s AstraZeneca AZN Stock Holding History

PCA Investment Advisory Services’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-97	Closed	-$13.9K	–	126
2023 Q2	$13.9K	Buy	+97	New	+$14.3K	0.01%	377

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PCA Investment Advisory Services's AZN Position: Q3 2023 in Review

PCA Investment Advisory Services sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 97 shares — an estimated $13.9K sold.

PCA Investment Advisory Services first reported a position in AZN in Q2 2023 and held it in 1 quarter. The position peaked at $13.9K in Q2 2023. 1,074 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

PCA Investment Advisory Services reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
PCA Investment Advisory Services sold 97 AstraZeneca shares in Q3 2023, an estimated $13.9K.
PCA Investment Advisory Services first reported a position in AstraZeneca in Q2 2023 and held it in 1 quarter.
PCA Investment Advisory Services's AstraZeneca position peaked at $13.9K in Q2 2023.
1,074 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on PCA Investment Advisory Services's 13F filing for Q3 2023, filed 13 Nov 2023.